Vanguard Group’s Enliven Therapeutics ELVN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $48.4M | Buy |
|
|||||
|
2025
Q1 | $38.8M | Sell |
|
|||||
|
2024
Q4 | $44.5M | Buy |
|
|||||
|
2024
Q3 | $49M | Buy |
|
|||||
|
2024
Q2 | $42.6M | Buy |
|
|||||
|
2024
Q1 | $20.8M | Sell |
|
|||||
|
2023
Q4 | $17M | Buy |
|
|||||
|
2023
Q3 | $15.7M | Buy |
|
|||||
|
2023
Q2 | $23.3M | Buy |
|
|||||
|
2023
Q1 | $3.33M | Buy |
|
|||||
|
2022
Q4 | $1.8M | Buy |
|
|||||
|
2022
Q3 | $693K | Buy |
|
|||||
|
2022
Q2 | $324K | Hold |
|
|||||
|
2022
Q1 | $500K | Sell |
|
|||||
|
2021
Q4 | $1.09M | Sell |
|
|||||
|
2021
Q3 | $1.98M | Buy |
|
|||||
|
2021
Q2 | $1.51M | Sell |
|
|||||
|
2021
Q1 | $1.94M | Buy |
|
|||||
|
2020
Q4 | $4.63M | Buy |
|
|||||
|
2020
Q3 | $3.91M | Sell |
|
|||||
|
2020
Q2 | $5.43M | Buy |
|
|||||
|
2020
Q1 | $599K | Buy |
|